🇺🇸 FDA
Pipeline program

NurOwn® (MSC-NTF cells)

BCT-002-US

Phase 3 mab completed

Quick answer

NurOwn® (MSC-NTF cells) for Amyotrophic Lateral Sclerosis (ALS) is a Phase 3 program (mab) at BRAINSTORM CELL THERAPEUTICS INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
BRAINSTORM CELL THERAPEUTICS INC.
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials